After several decades in development, two malaria vaccines based on the same antigen and
with very similar constructs and adjuvants, RTS, S/AS01 (RTS, S) and R21/Matrix-M (R21) …

Abstract Background The RTS, S/AS01E malaria vaccine has moderate efficacy, lower in
infants than children. Current efforts to enhance RTS, S/AS01E efficacy would benefit from …

Background RTS, S is the first malaria vaccine recommended for implementation among
young children at risk. However, vaccine efficacy is modest and short-lived. Antibodies play …

Abstract RTS, S/AS01E, the first approved malaria vaccine, demonstrated moderate efficacy
during the phase 3 pediatric trial. We previously investigated cell-mediated immune (CMI) …

Background The candidate malaria vaccine RTS, S/AS01 reduced episodes of both clinical
and severe malaria in children 5 to 17 months of age by approximately 50% in an ongoing …

Background The pre-erythrocytic malaria vaccine RTS, S/AS02A has shown to confer
protection against clinical malaria for at least 21 months in a trial in Mozambican children …

Chapter Summary RTS, S/AS01 is a preerythrocytic Plasmodium falciparum malaria vaccine
that has received a positive European Medicines Agency scientific opinion upon regulatory …

Background The candidate malaria vaccine RTS, S/AS01 is being evaluated in order to
inform a decision regarding its inclusion in routine vaccination schedules. Methods We …

Background An ongoing phase 3 study of the efficacy, safety, and immunogenicity of
candidate malaria vaccine RTS, S/AS01 is being conducted in seven African countries …

Development of an effective malaria vaccine that could be deployed widely in endemic
areas has proved to be more difficult than was anticipated, when the first clinical trials of …